WO2011139843A3 - Multi-sirna compositions for reducing gene expression - Google Patents

Multi-sirna compositions for reducing gene expression Download PDF

Info

Publication number
WO2011139843A3
WO2011139843A3 PCT/US2011/034354 US2011034354W WO2011139843A3 WO 2011139843 A3 WO2011139843 A3 WO 2011139843A3 US 2011034354 W US2011034354 W US 2011034354W WO 2011139843 A3 WO2011139843 A3 WO 2011139843A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
formulations
compositions
nucleic acid
reducing gene
Prior art date
Application number
PCT/US2011/034354
Other languages
French (fr)
Other versions
WO2011139843A2 (en
Inventor
Shaguna Seth
Kathy L. Fosnaugh
Yan Liu
Michael V. Templin
Original Assignee
Marina Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marina Biotech, Inc. filed Critical Marina Biotech, Inc.
Publication of WO2011139843A2 publication Critical patent/WO2011139843A2/en
Publication of WO2011139843A3 publication Critical patent/WO2011139843A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This disclosure provides formulations and compounds for use in treating disease by gene silencing and, more specifically, to formulations and compositions having multiple double- stranded nucleic acid complexes, each double- stranded nucleic acid complex comprising an antisense strand and a continuous passenger strand or a discontinuous passenger strand, where the composition decreases expression of one or more mRNA, and to uses of such formulations and compositions to treat or prevent diseases or conditions associated with inappropriate gene expression.
PCT/US2011/034354 2010-04-28 2011-04-28 Multi-sirna compositions for reducing gene expression WO2011139843A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32903410P 2010-04-28 2010-04-28
US61/329,034 2010-04-28

Publications (2)

Publication Number Publication Date
WO2011139843A2 WO2011139843A2 (en) 2011-11-10
WO2011139843A3 true WO2011139843A3 (en) 2012-01-26

Family

ID=44177466

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2011/034352 WO2011139842A2 (en) 2010-04-28 2011-04-28 Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
PCT/US2011/034354 WO2011139843A2 (en) 2010-04-28 2011-04-28 Multi-sirna compositions for reducing gene expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2011/034352 WO2011139842A2 (en) 2010-04-28 2011-04-28 Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof

Country Status (1)

Country Link
WO (2) WO2011139842A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
KR20150088305A (en) * 2012-11-26 2015-07-31 로슈 이노베이션 센터 코펜하겐 에이/에스 Compositions and methods for modulation of fgfr3 expression
KR102306656B1 (en) * 2013-07-03 2021-09-29 삼성전자주식회사 Combination therapy for the treatment of cancer using an anti-c-Met antibody
WO2016139227A1 (en) 2015-03-03 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Fgfr3 antagonists
CA3005937C (en) * 2015-12-13 2021-11-09 Nitto Denko Corporation Sirna structures for high activity and reduced off target

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
WO2008147824A2 (en) * 2007-05-22 2008-12-04 Mdrna, Inc. Hydroxymethyl substituted rna oligonucleotides and rna complexes
WO2010017311A2 (en) * 2008-08-05 2010-02-11 Mdrna, Inc. Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1339303C (en) 1987-09-21 1997-08-19 Lyle John Arnold Jr. Non-nucleotide linking reagents for nucleotide probes
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
EP0451221B1 (en) 1989-08-31 1994-10-12 City Of Hope Chimeric dna-rna catalytic sequences
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
WO1992007065A1 (en) 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
DE4216134A1 (en) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc Method and reagent for inhibiting viral replication.
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5767264A (en) 1993-01-22 1998-06-16 Mta Zozponti Kemiai Kutato Intezet Oligodeoxynucleotides containing 5-alkyl, 5-(1-alkenyl)- and 5-(1-alkynl) pyrimidines
DK0748382T3 (en) 1993-09-02 2003-02-17 Ribozyme Pharm Inc Enzymatic nucleic acid containing non-nucleotide
JPH09504297A (en) 1993-10-27 1997-04-28 リボザイム・ファーマシューティカルズ・インコーポレーテッド 2'-amide and 2'-peptide modified oligonucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
DE69527206T2 (en) 1994-09-30 2003-02-27 Inex Pharmaceuticals Corp AGENT FOR INSERTING POLYANIONIC MATERIALS IN CELLS
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
WO1996040961A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
AU1430097A (en) 1996-01-16 1997-08-11 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
AU738384B2 (en) 1996-11-04 2001-09-20 Qiagen Gmbh Cationic reagents for transfection
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
WO1999031262A2 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
ATE443528T1 (en) 1998-01-05 2009-10-15 Univ Washington INCREASED TRANSPORT USING MEMBRANE-DESTRUCTIVE SUBSTANCES
US6426086B1 (en) 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
AU3751299A (en) 1998-04-20 1999-11-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US20040132161A1 (en) 1998-04-20 2004-07-08 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
AU767195B2 (en) 1999-03-10 2003-11-06 Phogen Limited Delivery of substances to cells
US6849272B1 (en) 1999-04-21 2005-02-01 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
EP1102785B1 (en) 1999-06-07 2013-02-13 Arrowhead Research Corporation COMPOSITIONS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES
CN1228041C (en) 1999-07-15 2005-11-23 英耐克斯药品股份有限公司 Methods for preparation of lipid-encapsulated therapeutic agents
US6200599B1 (en) 1999-10-07 2001-03-13 The Regents Of The University Of California Ortho ester lipids
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
EP1203614A1 (en) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Process and apparatus for preparing lipid vesicles
US6897196B1 (en) 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
DE10109897A1 (en) 2001-02-21 2002-11-07 Novosom Ag Optional cationic liposomes and their use
US7108863B2 (en) 2001-03-26 2006-09-19 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
EP2823809B1 (en) 2002-06-28 2016-11-02 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
JP4951338B2 (en) 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド Interfering RNA encapsulated in lipid
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
EP1773998A2 (en) 2004-04-20 2007-04-18 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
WO2005116204A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
WO2008031202A1 (en) 2006-09-11 2008-03-20 Research In Motion Limited Apparatus, and associated method, for paging an access terminal in a radio communication system
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
NZ580707A (en) 2007-05-04 2011-11-25 Marina Biotech Inc Acylated cationic amino acids and uses thereof
JP2011530289A (en) * 2008-08-05 2011-12-22 マリーナ バイオテック，インコーポレイテッド Nucleic acid compound and its use for suppressing expression of PLK1 gene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
WO2008147824A2 (en) * 2007-05-22 2008-12-04 Mdrna, Inc. Hydroxymethyl substituted rna oligonucleotides and rna complexes
WO2010017311A2 (en) * 2008-08-05 2010-02-11 Mdrna, Inc. Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GILL CATHERINE ET AL: "Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 1, 23 June 2009 (2009-06-23), pages 39, XP021058727, ISSN: 1476-4598, DOI: DOI:10.1186/1476-4598-8-39 *
JI J ET AL: "Enhanced gene silencing by the application of multiple specific small interfering RNAs", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 552, no. 2-3, 25 September 2003 (2003-09-25), pages 247 - 252, XP004460905, ISSN: 0014-5793, DOI: DOI:10.1016/S0014-5793(03)00893-7 *
K. TIEMANN ET AL: "Dual-targeting siRNAs", RNA, vol. 16, no. 6, 21 April 2010 (2010-04-21), pages 1275 - 1284, XP055002804, ISSN: 1355-8382, DOI: 10.1261/rna.2005710 *
L. ZHU: "Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma", MOLECULAR CANCER THERAPEUTICS, vol. 4, no. 5, 1 May 2005 (2005-05-01), pages 787 - 798, XP055001610, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-04-0330 *
MARIA LAURSEN: "Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo", MOLECULAR BIOSYSTEMS, 9 February 2010 (2010-02-09), pages 862 - 870, XP055000712 *
SOMMER ET AL: "Oncogenic c-H-ras deregulates survivin expression: An improvement for survival", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 581, no. 25, 8 October 2007 (2007-10-08), pages 4921 - 4926, XP022289815, ISSN: 0014-5793, DOI: DOI:10.1016/J.FEBSLET.2007.09.023 *
T L CHENG ET AL: "Multitarget therapy of malignant cancers by the head-to-tail tandem array multiple shRNAs expression system", CANCER GENE THERAPY, vol. 16, no. 6, 1 June 2009 (2009-06-01), pages 516 - 531, XP055002851, ISSN: 0929-1903, DOI: 10.1038/cgt.2008.102 *
YAN-BIN FENG ET AL: "Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma", INTERNATIONAL JOURNAL OF CANCER, vol. 124, no. 3, 1 February 2009 (2009-02-01), pages 578 - 588, XP055002858, ISSN: 0020-7136, DOI: 10.1002/ijc.23990 *
YANG DEYONG ET AL: "Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells", ACTA BIOCHIMICA ET BIOPHYSICA SINICA, vol. 42, no. 2, February 2010 (2010-02-01), pages 137 - 144, XP002650488 *

Also Published As

Publication number Publication date
WO2011139843A2 (en) 2011-11-10
WO2011139842A3 (en) 2012-01-26
WO2011139842A2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
WO2013074974A3 (en) Modified rnai agents
WO2010033247A3 (en) Reduced size self-delivering rnai compounds
WO2014022739A3 (en) Modified rnai agents
WO2010065756A3 (en) Usirna complexes
WO2007134161A8 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
WO2014043289A3 (en) Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof
WO2011116152A3 (en) Delivery of agents using interfering nanoparticles
EP2788087A4 (en) Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
WO2010093705A3 (en) Synthetic rna-based agonists of tlr7
WO2008109369A3 (en) Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
WO2007128477A3 (en) SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION
WO2009105260A3 (en) Ultra-small rnas as toll-like receptor-3 antagonists
WO2008036933A3 (en) Compositions and methods for inhibiting expression of the hamp gene
WO2008008719A3 (en) Compositions and methods for inhibiting expression of the myc gene
WO2008036638A3 (en) Rnai modulation of scap and therapeutic uses thereof
WO2007137156A8 (en) Rnai modulation of aha and therapeutic uses thereof
WO2008045576A3 (en) Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2011139843A3 (en) Multi-sirna compositions for reducing gene expression
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2008109516A3 (en) Nucleic acid compounds for inhibiting ras gene expression and uses thereof
WO2011133584A8 (en) Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2010017311A3 (en) Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof
WO2008109352A3 (en) Nucleic acid compounds for inhibiting akt gene expression and uses thereof
WO2008109375A3 (en) Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
WO2011103028A3 (en) Compositions and methods for inhibiting mmset

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11719717

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11719717

Country of ref document: EP

Kind code of ref document: A2